✦ LIBER ✦

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b

✍ Scribed by A. Abergel; C. Hezode; V. Leroy; K. Barange; J. P. Bronowicki; A. Tran; L. Alric; L. Castera; P.-H. Bernard; C. Henquell; H. Lafeuille; S. Ughetto; C. Darcha; M. Chevallier; N. Martineau; S. Dubost; K. Randl; D. Dhumeaux; G. Bommelaer; C. Bonny; a French multicenter study group

Book ID: 108885925
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 490 KB
Volume: 13
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2006.00768.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early virologic response after peginterf

Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C

✍ A. M. Di Bisceglie; R. H. Ghalib; F. M. Hamzeh; V. K. Rustgi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 547 KB

Comment on a systematic review of random

Comment on a systematic review of randomized trials of peginterferon alpha-2a versus peginterferon alpha-2b in chronic hepatitis C

✍ Ashwani K. Singal; Sarat C. Jampana; Bhupinderjit S. Anand 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 352 KB

We read with interest the article by Vibert et al. 1 recently published in HEPATOLOGY. The authors described their single-center experience with liver transplantation for hepatocellular carcinoma (HCC) in human immunodeficiency virus (HIV)-positive patients (21 cases) and compared those patients to

Proceed with caution: Peginterferon alph

Proceed with caution: Peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials

✍ David Kershenobich; Linda Muñoz; René Malé; Jesús Gaytan; Francisco Sánchez 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB

We read with great interest the article by Cavazza et al., 1 who demonstrated that an advanced histological stage was the only risk factor associated with the development of hepatocellular carcinoma (HCC) in patients with primary biliary cirrhosis (PBC) from two European centers. Similar results wer

Peginterferon alpha-2a is associated wit

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials

✍ Tahany Awad; Kristian Thorlund; Goran Hauser; Davor Stimac; Mahasen Mabrouk; Chr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 440 KB 👁 1 views

A combination of weekly pegylated interferon (peginterferon) alpha and daily ribavirin represents the standard of care for the treatment of chronic hepatitis C according to current guidelines. It is not established which of the two licensed products (peginterferon alpha-2a or peginterferon alfa-2b)

Clinical trial: extended treatment durat

Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders

✍ M. NAGAKI; M. SHIMIZU; J. I. SUGIHARA; E. TOMITA; C. SANO; T. NAIKI; K. KIMURA; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB

PHOENIX: A randomized controlled trial o

PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus

✍ Natalie Bzowej; David R. Nelson; Norah A. Terrault; Gregory T. Everson; Lichen L 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB 👁 2 views

The efficacy, tolerability, and safety of the prophylactic treatment of hepatitis C virus (HCV) after liver transplantation (LT) with peginterferon alfa-2a and ribavirin are not known. LT recipients with HCV were randomized to peginterferon alfa-2a/ribavirin treatment or observation 10 to 26 weeks p